IL6 and rheumatoid arthritis: Biologics targeted to IL-6, such as tocilizumab, a humanized monoclonal antibody generated to the IL-6 receptor, are licensed for the management of active rheumatoid arthritis, juvenile idiopathic arthritis, and replasing or refractory giant cell arteritis (GCA) (6).